Developing a Novel Therapy for Rhabdomyolysis
Abstract
The purpose of this project is to determine the optimal dose and timing of cilastatin therapy to determine strategies to mitigate acute kidney injury (AKI), and to determine whether or not the pragmatic administration of cilastatin prevents rhabdomyolysis induced AKI (rhAKI), hyperkalemia, and mortality caused by a combat-relevant model of severe musculoskeletal trauma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190393
Entities
People
- Michael P. Hutchens
Organizations
- Oregon Health & Science University